New Research Report on Global Statins Market to 2018 by MarketResearchReports
New Market Research Report Added In MarketResearchReports.Biz Database Statins Market to 2018 - Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share.
Albany, NY, February 01, 2013 --(PR.com)-- GBI Research, the leading business intelligence provider, has released its latest research, Statins Market to 2018 Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share, which provides insights into the global statins market until 2018.
The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Researchs team of industry experts. The report provides an in-depth analysis of the global statins market for dyslipidemia.
To Buy the Copy of This Report visit: http://www.marketresearchreports.biz/analysis-details/statins-market-to-2018-weak-product-pipeline-and-shift-of-focus-towards-combination-therapies-will-lead-to-erosion-of-brand-share.
The report gives insights into the share of generics in the global statins market for the years 2011 and 2018. The report examines the dyslipidemia treatment usage patterns in the US, the top five countries of Europe (The UK, France, Germany, Spain and Italy), and Japan.
In addition to the global market landscape for statins, the report also provides details of the geographical distribution of statins sales in the major markets, including the US, the top five countries of Europe, and Japan. The report also includes insights into the statins R&D product pipeline, and explores the competitive landscape, including major players in the statins market. Finally, the report also includes analysis on mergers and acquisitions (M&A) and licensing and co-development deals that have taken place in the statins market.
Statins have dominated the global dyslipidemia therapeutics market for the last few decades. The National Cholesterol Education Program (NECP) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines have recommended the use of statins as the first choice of pharmacotherapy for the treatment of dyslipidemia. The global statins market, valued at $20.5 billion in 2011, is forecast to decline at a negative Compound Annual Growth Rate (CAGR) of 7.2% over the next seven years, to reach $12.2 billion by 2018.
Scope
Data and analysis on the statins market in the leading geographies of the world the US, the UK, Germany, France, Italy, Spain, and Japan.
Annualized market data for the statins market from 2004 to 2011, with forecasts to 2018.
Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment-seeking population, diagnosis population and prescription population.
Share of generics in the global statins market.
Reasons to buy
Align their product portfolio to the markets with high growth potential
Build effective strategies to launch their pipeline products by identifying potential geographies
Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps
Develop key strategic initiatives by studying the key strategies of top competitors
To Read the Complete Report with TOC Visit: http://www.marketresearchreports.biz/analysis/160067
For More Information Kindly Contact:
Hemendra Parmar
State Tower
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
sales@marketResearchReports.biz
website: http://www.marketresearchreports.biz/
Blog: http://mrrbiz.blogspot.com/
The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Researchs team of industry experts. The report provides an in-depth analysis of the global statins market for dyslipidemia.
To Buy the Copy of This Report visit: http://www.marketresearchreports.biz/analysis-details/statins-market-to-2018-weak-product-pipeline-and-shift-of-focus-towards-combination-therapies-will-lead-to-erosion-of-brand-share.
The report gives insights into the share of generics in the global statins market for the years 2011 and 2018. The report examines the dyslipidemia treatment usage patterns in the US, the top five countries of Europe (The UK, France, Germany, Spain and Italy), and Japan.
In addition to the global market landscape for statins, the report also provides details of the geographical distribution of statins sales in the major markets, including the US, the top five countries of Europe, and Japan. The report also includes insights into the statins R&D product pipeline, and explores the competitive landscape, including major players in the statins market. Finally, the report also includes analysis on mergers and acquisitions (M&A) and licensing and co-development deals that have taken place in the statins market.
Statins have dominated the global dyslipidemia therapeutics market for the last few decades. The National Cholesterol Education Program (NECP) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines have recommended the use of statins as the first choice of pharmacotherapy for the treatment of dyslipidemia. The global statins market, valued at $20.5 billion in 2011, is forecast to decline at a negative Compound Annual Growth Rate (CAGR) of 7.2% over the next seven years, to reach $12.2 billion by 2018.
Scope
Data and analysis on the statins market in the leading geographies of the world the US, the UK, Germany, France, Italy, Spain, and Japan.
Annualized market data for the statins market from 2004 to 2011, with forecasts to 2018.
Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment-seeking population, diagnosis population and prescription population.
Share of generics in the global statins market.
Reasons to buy
Align their product portfolio to the markets with high growth potential
Build effective strategies to launch their pipeline products by identifying potential geographies
Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps
Develop key strategic initiatives by studying the key strategies of top competitors
To Read the Complete Report with TOC Visit: http://www.marketresearchreports.biz/analysis/160067
For More Information Kindly Contact:
Hemendra Parmar
State Tower
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
sales@marketResearchReports.biz
website: http://www.marketresearchreports.biz/
Blog: http://mrrbiz.blogspot.com/
Contact
Market Research Reports.biz
Hemendra Parmar
+1-518-618-1030
www.marketresearchreports.biz
Hemendra Parmar
+1-518-618-1030
www.marketresearchreports.biz
Contact
Categories